impaired. There is an increase in not only collagen synthesis, but also in its crosslinking, increasing the stiffness of the myocardium (Querejeta et al. 2004 ). This extensive fibrotic deposition is associated with many overlapping exacerbating factors such as diabetes and aging, and treatment of fibrosis may attenuate such conditions (Tarone et al. 2014 ).
After myocardial infarction (MI), which results in wide-scale necrotic loss of cardiomyocytes, cardiac fibrosis arises in two ways. First, the limited regenerative capacity of cardiomyocytes requires the rapid formation of a fibrotic scar (Prabhu and Frangogiannis 2016) .
This initial reparative fibrosis is crucial as it prevents the rupture of the ventricular wall, although excessive scar expansion can actually impair the mechanical function of the heart (Czubryt 2012). Second, at longer time-points post-MI, an exaggerated fibrotic response extending well beyond the margin of the infarcted border zone occurs, resulting in cardiac stiffening (Talman and Ruskoaho 2016) . This secondary fibrosis may arise from altered mechanical stress occurring throughout the heart due to altered vectoring of physical force through the myocardium necessitated by the presence of the large, akinetic collagen-rich scar.
Increased cardiac afterload may be sufficient to result in a state of pressure overload, and is caused by precipitating factors such as cardiac valve dysfunction or hypertension. In response, a robust interstitial fibrosis can develop over time, likely as a response to increased transmural pressure (Czubryt 2012) . Concentric hypertrophy of the myocardium and increased interstitial fibrosis can contribute to a reduction in chamber volume and increased myocardial stiffness, impairing the cardiac filling in diastole. Fibrosis will continue to worsen while the underlying cause of the pressure overload persists (Debonnaire et al. 2015) .
Besides the impairment of mechanical function that fibrosis exerts on the heart, interstitial fibrosis and the fibrous post-MI scar can interfere with the normal electrical activity of the heart, D r a f t 6 leading to the development of arrhythmias (de Jong et al. 2011) . Both the scar and regions of fibrosis, in the form of foci or diffuse, patchy ECM-rich bands, possess different electrical properties from the surrounding cardiomyocytes, behaving as an electrical insulator. Fibrotic areas can thus either slow or block conduction of the action potential, predisposing individuals to potentially fatal arrhythmias and sudden cardiac death. Not surprisingly, cardiac fibrosis is thus an independent risk factor for overall mortality, sudden cardiac death and the requirement for implantation of a cardioverter-defibrillator in heart failure patients (Almehmadi et al. 2014 ).
Other cardiac disorders such as cardiomyopathies can also have a significant role in contributing to cardiac fibrosis. For example, mutations in sarcomere genes encoding key contractile proteins in cardiomyocytes, such as myosin heavy chain beta 7 (MYH7) and cardiactype myosin binding protein C (MYBPC3), can result in familial hypertrophic cardiomyopathy (Bonne et al. 1998 ). This cardiomyopathy is a primary genetic disease of cardiomyocytes, and the resulting impairment in normal cardiac function leads to activation of pro-fibrotic signaling pathways, resulting in interstitial fibrosis, arrhythmias and increased risk of sudden cardiac D r a f t 7 thought. In the heart, cytokines released by a variety of inflammatory cells can play a significant role in the activation of myofibroblasts, resulting in fibrosis. In addition, the release of myriad proteases by inflammatory cells results in ECM degradation and remodeling. Inflammatory cells, including monocytes, macrophages, lymphocytes and mast cells, are thus important modulators of cardiac fibrosis (Kong et al. 2014) . The inflammatory response can also be induced or exacerbated by cardiac endothelial cells, which can recruit monocytes and macrophages via the release of multiple cytokines, chemokines and pro-fibrotic mediators, such as transforming growth factor β (TGFβ), fibroblast growth factors or endothelin-1 (Wynn 2008) .
After MI, numerous inflammatory cells including neutrophils and macrophages infiltrate the injury site, releasing a pool of cytokines such as tumor necrosis factor α (TNFα), and interleukins (IL) IL-1β and IL-6β (Travers et al. 2016) . Pro-inflammatory cytokines upregulated after myocardial infarction can also be released by activated cardiac fibroblasts to facilitate further fibroblast proliferation and expansion of myocardial fibrosis (Travers et al. 2016) . In myocarditis or acute inflammatory cardiomyopathy, T-lymphocytes secrete cytokines that modulate collagen synthesis and the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), resulting in ECM remodeling (Wei 2011) . Inflammatory cells are also a direct source of pro-fibrotic growth factors such as TGFβ, platelet-derived growth factors (PDGF) and fibroblast growth factors, which directly stimulate proliferation of fibroblasts and their conversion to myofibroblasts (Kong et al. 2014) . In turn, activated fibroblasts can also serve as an additional source of these growth factors.
In patients with heart failure, elevated levels of "stress-mediated" pro-inflammatory cytokines such as TNFα, IL-6, and IL-1β are powerful predictors of poor prognosis. These . While the direct involvement of lymphocytes in cardiac fibrosis is incompletely characterized, CD4+ helper cells may up-regulate pro-fibrotic cytokines IL-4 and IL-13, which can work as potent stimulators for fibroblast collagen synthesis in the myocardium (Wynn 2008) .
Besides monocytes and macrophages, cardiac mast cells have also been implicated in the fibrotic remodeling of the heart by playing a significant role in the production various types of fibrotic mediators, growth factors, vasoactive agents and cytokines that are capable of mediating cardiac remodeling (Batlle et al. 2007 ).
Cardiac transplantation is often a strategy of last resort for the treatment of heart failure patients, however cardiac allograft rejection due to activation of an anti-graft immune response can also lead to cardiac fibrosis and vasculopathy. Graft rejection is characterized by basophilmediated release of cytokines that activate the donor-derived fibroblasts to produce an excessive amount of ECM (Pichler et al. 2012; Schiechl et al. 2016) . Patients with late-failing cardiac allografts exhibit occlusive narrowing of the coronary vessels and progressive replacement fibrosis of the parenchyma, which devolves over time to induce cardiac dysfunction (Libby and D r a f t MMPs in order to maintain ECM homeostasis in the otherwise healthy heart. Following conversion to myofibroblasts, ECM synthesis is dramatically increased, which overtime leads to fibrosis. Myofibroblasts not only express high levels of fibrillar collagens, but also exhibit increased expression of various markers such as fibronectin and vimentin (Bagchi et al. 2016b; Santiago et al. 2010 ). In addition, proteins not expressed in fibroblasts are induced, including periostin as well as α-smooth muscle actin (αSMA) which confers myofibroblast contractility (Bagchi et al. 2016b) . Recently it was shown that all periostin-expressing myofibroblasts arise from Tcf21-expressing cardiac fibroblasts, and that deletion of periostin-positive cells reduces generation of the scar post-MI (Kanisicak et al. 2016) . This finding is striking, since it was previously demonstrated that Tcf21 gene deletion results in the absence of cardiac fibroblasts (Acharya et al. 2012 ). Thus, a Tcf21-positive lineage appears to represent at least the large majority of cardiac fibroblasts that contribute to healing after infarction.
Periostin-positive myofibroblasts appear to somewhat reverse their phenotype, becoming more like fibroblasts, following infarct healing, however it has also been reported that activated myofibroblasts may persist in the heart even decades after the initial injury, contributing to fibrosis (Kanisicak et al. 2016; Willems et al. 1994) . Temporary fibroblast activation to myofibroblasts is a key event in dermal wound healing, but eventually these myofibroblasts undergo apoptosis and effectively vanish once the injury is fully healed (Czubryt 2012). It is thus tempting to speculate that the development of fibrosis in the heart results from an impairment of apoptosis, from a failure of myofibroblasts to revert to fibroblasts, or from some combination of the two phenomena.
It has been proposed that other cell populations can undergo phenotype conversion to a myofibroblast-like phenotype. For example, endothelial cells may undergo endothelial-D r a f t mesenchymal transition (EndMT), a process that may be important in fibrotic development following pressure overload (Zeisberg et al. 2007) . Similarly, epithelial-mesenchymal transition (EMT) may also contribute to scar formation (Zhou and Pu 2011) . Finally, it has been proposed that circulating myeloid cells may invade the myocardium, where they may stimulate endogenous cells to convert to myofibroblasts or possibly even convert to a myofibroblast-like state themselves (Haudek et al. 2006) . Ultimately, the most important source of myofibroblasts may vary depending on the specific nature of the cardiac insult (Crawford et al. 2012 ).
Circulating fibrocytes are another potential source of collagen during the development of cardiac fibrosis (Lin et al. 2016) . These multifunctional, monocyte-derived cells exhibit features of both macrophages and fibroblasts (Bucala et al. 1994) . Upon cardiac insult, the local release of chemotactic factors attracts circulating fibrocytes from the bloodstream to the heart. Initially, fibrocytes are involved in the inflammatory process, expressing hematopoietic genes encoding chemokine receptors and cytokines such as CD34 and CD45, facilitating recruitment of additional inflammatory cells (Reilkoff et al. 2011) . As the transition to the remodeling phase begins, fibrocytes differentiate into myofibroblast-like cells, up-regulating expression of α-SMA, fibronectin and collagen, and down-regulating expression of CD34 and CD45 (Kao et al. 2011 ).
This process is facilitated by TGFβ (Abe et al. 2001) . Multiple experimental studies have shown that the level of circulating fibrocytes is highly elevated in the heart, and in correlation with the degree of cardiac fibrosis, in a host of cardiac pathologies including hypertension, heart failure, atrial fibrillation and even natural aging (Chu et al. 2010; Keeley et al. 2012; Szardien et al. 2012; Xie et al. 2014 ). However, while it is clear that fibrocytes can adopt a myofibroblast-like phenotype, it is still unclear to what degree this process actually contributes to fibrosis. Connective tissue growth factor (CTGF), also known as CCN2, is a matricellular protein that has been implicated in modulating the pathological cardiac remodeling process (Daniels et al.
2009). Expression of CTGF in myocytes and fibroblasts is induced by many factors including
TGFβ, AngІІ, aldosterone, endothelin-1 and mechanical stress (Travers et al. 2016) . A number of studies have shown that CTGF mRNA and protein levels are strongly up-regulated in many cardiac disease conditions (Au et al. 2011) . Interestingly, these levels are elevated even before D r a f t 13 the induction of TGFβ expression or initiation of the fibrotic process, implicating CTGF in collagen synthesis and formation of the fibrotic scar (Duncan et al. 1999) . Persistent fibrotic tissue formation may require the contribution of both TGFβ to induce fibrosis, and CTGF to maintain it (Mori et al. 1999 ).
PDGF has also been implicated in the pathogenesis of cardiac fibrosis by inducing TGFβ synthesis, while conversely TGFβ induces PDGF production (Czuwara-Ladykowska et al. 2001; Zhao et al. 2013) . After MI, PDGF signals through PDGF receptors α and β to activate overlapping signal transduction pathways, including phosphatidylinositol 3-kinase, Ras-MAPK, Src family kinases, and phospholipase Cγ, promoting collagen deposition, stimulating fibroblast proliferation and stabilizing the scar (Taylor 2000) .
Besides growth factors, changes in physical forces applied to fibroblasts, including surrounding matrix tension and mechanical stretch, may also induce conversion to myofibroblasts and subsequent ECM synthesis. It has long been known that plating primary fibroblasts onto firm substrates, including even tissue culture plastic ware, induces rapid conversion to myofibroblasts (Hinz 2009). Physical force, acting through integrins, up-regulates multiple pro-fibrotic genes including α-SMA and fibrillar collagens І and ІІІ (Carver et al. 1991; Roche et al. 2016) . The resulting increase in ECM synthesis may represent an attempt to resist excessive extracellular forces via the construction of stronger matrix. The induction of fibroblast phenotype transition would be expected to result in increased cell adherence to the surrounding matrix, attenuating their migration and proliferation to contribute to scar maturation and stability (Tomasek et al. 2002) .
Our laboratory has reported that a transcription factor called scleraxis is a central Scleraxis expression is induced by pro-fibrotic TGFβ/Smad3 signaling, and reduced by inhibitory Smad7 (Bagchi and Czubryt 2012) . TGFβ also appears to be capable of inducing scleraxis expression via a Smad-independent non-canonical pathway, possibly through c-Jun which has also been implicated in fibrosis (Zeglinski et al. 2016) . Given the central roles of these pathways in fibrosis, it is thus not surprising that scleraxis expression increases significantly in the cardiac infarct scar, suggesting it may play a key causative role in the fibrotic process in vivo (Espira et al. 2009 ). Mechanical stretch also induces scleraxis expression, and knockdown of scleraxis attenuates the ability of stretch to cause fibroblast to myofibroblast conversion (Roche et al. 2016) . However, while stretch causes transactivation of the scleraxis promoter, the precise mechanism and transcriptional regulator involved is yet to be elucidated.
Current Treatments for Cardiac Fibrosis
Despite the fact that cardiac fibrosis represents a significant risk factor for patient morbidity and mortality, at present there are no pharmacological treatments that directly target the fibrotic process. Given the vast pharmacopoeia available for treating cardiovascular disorders in general, this treatment gap is particularly conspicuous, and presents a key weakness in the management of cardiac patients. There are a number of reasons why treatment strategies for cardiac fibrosis are lacking, despite a number of efforts in this regard. Part of the problem is that, until recently, At present, while direct inhibition of fibrosis mechanisms has remained elusive, modest success has instead come from treating the underlying cardiovascular pathologies that initiate or facilitate the development of fibrosis, or from delivering cardioprotective drugs to reduce stress and damage to the heart. In some cases, these approaches appear to work via secondary Surgical resection of scar tissue is another strategy that has been used therapeutically -not to treat fibrosis itself, but instead to reduce arrhythmias arising from the electrical heterogeneity introduced by scar tissue. Encircling endocardial ventriculotomy was used to treat patients with ventricular tachycardia post-MI, and who were resistant to medical treatment. By excluding the D r a f t damaged region of the myocardium, this approach successfully eliminated tachyarrhythmias in a small number of patients up to 24 months after surgery (Guiraudon et al. 1978) .
Novel Approaches to Treating Cardiac Fibrosis
The quest for new therapies that specifically target the underlying mechanisms of fibrosis continues, and in fact is accelerating as the critical role played by fibrosis in tissue dysfunction throughout the body becomes more apparent. Large numbers of potential inhibitors of fibrosis are currently under study, although in many cases the mechanism of action is unknown (Nanthakumar et al. 2015) . One small molecular inhibitor that has passed beyond clinical trials to human use is pirfenidone.
A number of studies have investigated the therapeutic effect of pirfenidone on fibrotic disease in various animal models and multiple organs, including the lungs, kidneys, liver and heart (Schaefer et al. 2011) . Following extensive clinical trials, pirfenidone was approved for clinical use in idiopathic pulmonary fibrosis (IPF) under the trade name Esbriet (Bando 2016).It appears capable of slowing or inhibiting the progression of fibrotic lesions, and prevents the formation of new lesions following injury, however it is noteworthy that its mechanism of action is still not fully understood. While clearly not a cure for IPF, pirfenidone has nonetheless demonstrated clinically significant improvements in lung function and survival of patients with mild to moderate IPF both in clinical trials and in real-world usage (Noble et al. 2016) . It has not yet been widely approved for patient use in other tissues, although liver fibrosis and chronic dermal wounds are promising targets.
Pirfenidone alters expression of type I collagen, as well as of cytokines including TGFβ, TNFα, and PDGF, attenuating fibrosis in various chronic diseases, although exactly how it exerts D r a f t 20 these effects is unclear (Lopez-de la Mora et al. 2015) . In vitro studies have demonstrated that pirfenidone, when applied to isolated cardiac fibroblasts, reduces the synthesis and secretion of TGFβ, modulates fibroblast proliferation and attenuates αSMA expression and cell contractility (Shi et al. 2011) . Pirfenidone attenuated cardiac remodeling in hypertensive rats independently of blood pressure, in a post-MI rat model reduced scar size, improved left ventricular function and decreased the incidence of arrhythmias (Mirkovic et al. 2002; Nguyen et al. 2010) . Pirfenidone thus shows promise for the modulation of cardiac fibrosis in human disease.
Pirfenidone can also act as an immune modulator, and has been used in allograft rejection to minimize the amount of scarring following surgery (Visner et al. 2009 ). To this end, pirfenidone has been shown to suppress inflammasome formation in cardiac remodeling induced by pressure overload (Roche and Czubryt 2013; Wang et al. 2013) . Thus it is possible that pirfenidone exerts its action, not directly on the intracellular mechanism of fibrosis, but rather on inflammation that activates the fibrotic process upstream of these pathways. Supporting data for this model comes from a study in which oral pirfenidone was administered to mdx Duchenne muscular dystrophy mice, resulting in an improvement in cardiac contractility but without a change in cardiac stiffness or in the amount of fibrosis, suggesting that the drug's mechanism of action is not on fibrotic intracellular signaling pathways (Van Erp et al. 2006 ).
The only other drug currently approved specifically for treating a fibrotic disease in humans is nintedanib, which, like pirfenidone, has been approved for IPF, and which is also undergoing clinical trials for systemic sclerosis (Fala 2015) . Unlike pirfenidone, there is a better understanding of the mechanism of action of nintedanib, which blocks various receptor tyrosine kinases implicated in fibrosis including those of PDGF, fibroblast growth factor and vascular endothelial growth factor (Nanthakumar et al. 2015) . This drug has shown significant anti-D r a f t 21 fibrotic and anti-inflammatory properties in animal models of IPF (Wollin et al. 2014) . Despite the promising nature of nintedanib, it has not yet been tested in animal models of cardiac fibrosis.
The central role for scleraxis in mediating fibroblast and myofibroblast phenotype makes it an intriguing target for the development of anti-fibrotic therapies. In our various studies, any interference with scleraxis function -whether by gene deletion, knockdown, use of a dominant negative, or alteration of post-translational modifications -attenuated evidence of fibroblast to myofibroblast transition and reduced expression of collagen, other ECM components or myofibroblast markers (Bagchi and Czubryt 2012; Bagchi et al. 2016a; Bagchi et al. 2016b; Bagchi et al. 2016c; Espira et al. 2009; Roche et al. 2016) . This effect occurred regardless of whether the upstream inducer of fibrosis was TGFβ, Smad3 or mechanical stretch, suggesting that scleraxis acts as a signaling nexus upon which multiple pro-fibrotic pathways descend.
Drugging scleraxis may thus have the dual benefits of reducing off-target effects and increasing efficacy by blocking the common effector of multiple fibrotic signaling pathways, rather than by targeting upstream inducers of these pathways such as cytokines or their receptors. Furthermore, if scleraxis is involved in fibrotic diseases of other tissues such as the lung or kidneys, the creation of anti-scleraxis therapies may provide the added benefit of having a single treatment for fibrosis regardless of the tissue type involved.
There are several strategies that could be developed to target scleraxis. One approach is knockdown via adenovirus-mediated gene delivery of a suitable, specific shRNA. We have successfully employed this approach in vitro to nearly eliminate scleraxis levels and attenuate scleraxis-dependent ECM gene expression (Bagchi et al. 2016a; Bagchi et al. 2016b; Roche et al. 2016) . A potential refinement for this approach would be to drive the expression of the shRNA D r a f t with a cell type-specific gene promoter, such as that for TCF21, which would facilitate delivery to cardiac fibroblasts but not to other cells of the myocardium, thus reducing off-target effects (Acharya et al. 2012 ). This approach would also permit tuning of the degree of knockdown by controlling viral load, as well as of the length of treatment. The use of drug-inducible promoters could permit further refinement. Alternatively, it may be possible to alter scleraxis activity, rather than expression, via the development of small molecule inhibitors. Our work has shown that scleraxis requires constitutive phosphorylation for its transactivation activity, and that scleraxis activity further relies on its ability to bind to protein partners and DNA (Bagchi and Czubryt 2012; Bagchi et al. 2016b; Bagchi et al. 2016c; Espira et al. 2009) . These requirements open the door to novel ways to interfere with scleraxis function. Other laboratories have demonstrated the attenuation of the activity of transcription factors such as NOTCH via the use of specific inhibitors such as stapled peptides -an approach that may be similarly useful for scleraxis (Moellering et al. 2009 ).
Conclusion
Cardiac fibrosis is a common pathology that is both a response to stress and damage, and a cause of further dysfunction leading to heart failure. Its very ubiquity, coupled with its significant negative impact on patient outcomes, requires a concerted effort to develop novel treatments to either arrest the progress of fibrosis, or even to reverse it. New treatments like pirfenidone, and new targets like scleraxis, provide tantalizing approaches that may be capable of achieving these therapeutic goals. Further research in this field is urgently needed, and has tremendous potential to exert powerful positive effects on the health and survival of patients with fibrotic diseases. lead to cardiac stress and damage (white ovals), which in turn directly or indirectly promote cardiac fibrosis. Over time, fibrosis adversely affects cardiac function by promoting arrhythmogenesis or systolic and diastolic dysfunction (dark gray ovals), ultimately leading to significant pathological outcomes including heart failure and sudden cardiac death (black boxes).
Some initiating events, such as diabetes and aging, promote fibrosis through mechanisms that remain poorly described (dashed arrows). 
